Etentamig with Iberdomide

Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Arms / Cohorts

Experimental:Phase 2: ABBV-383 Dose Expansion Dose A

Not yet accepting

Experimental:Phase 1: ABBV-383 Dose Escalation

Accepting patients

Experimental:Phase 2: ABBV-383 Dose Expansion Dose B

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.